Search

Displaying results 3491 - 3500 of 8700 in total
  1. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  2. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...

  3. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    PH-COPD). … Frespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With

  5. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  6. Drug

    Stannous chloride

    go.drugbank.com/drugs/DB11056
    Approved

    These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].

  7. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    It is not an approved drug.

    Mixtures: GONGFUTOUYANG protein conditioner for
  8. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder ...

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  9. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition.

    Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 Substrates
  10. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates